The EEF2 gene spinocerebellar ataxia type 26 (SCA26) autosomal dominant genetic test is a specialized diagnostic tool used to detect mutations in the EEF2 gene, which have been linked to SCA26. Spinocerebellar ataxia type 26 is a rare, inherited neurological disorder characterized by progressive coordination problems, difficulty walking, and other motor system impairments due to cerebellar atrophy. Since SCA26 follows an autosomal dominant inheritance pattern, having just one copy of the altered gene is sufficient to cause the disorder.
This genetic test is crucial for individuals with a family history of SCA26 or those showing symptoms suggestive of the condition. Early and accurate diagnosis through this test can aid in the management of symptoms, genetic counseling, and planning for the future.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. By opting for this test at DNA Labs UAE, patients and their families can expect reliable results, comprehensive support, and guidance on the implications of the findings for their health and lifestyle.
The FGF14 gene, associated with Spinocerebellar Ataxia Type 27 (SCA27), is a critical area of genetic study due to its implications in the development of this specific type of ataxia. Spinocerebellar ataxia is a progressive, neurodegenerative condition characterized by coordination and balance difficulties, stemming from the cerebellum's degeneration. SCA27, in particular, is distinguished by its genetic link to mutations in the FGF14 gene, which plays a significant role in the functioning of neurons in the cerebellum.
Recognizing the importance of early diagnosis and the potential for family planning and management, DNA Labs UAE offers a specialized genetic test targeting the FGF14 gene to identify mutations associated with Spinocerebellar Ataxia Type 27. This test is vital for individuals with a family history of SCA27 or those exhibiting symptoms suggestive of spinocerebellar ataxias.
The testing process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the FGF14 gene that are known to cause SCA27. This autosomal dominant condition means a single copy of the altered gene in each cell is sufficient to cause the disorder, making the identification of such mutations critical for affected families.
The cost of the FGF14 gene test for Spinocerebellar Ataxia Type 27 at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, including the sophisticated techniques used to detect genetic variations accurately, and the expertise required to interpret the results. Given the complexity of genetic testing and the potential implications of the results, genetic counseling is often recommended alongside testing to provide individuals and families with the support and information needed to understand their risk and options moving forward.
The AFG3L2 gene plays a crucial role in the development and maintenance of the nervous system. Mutations in this gene are directly linked to Spinocerebellar Ataxia Type 28 (SCA28), a rare, autosomal dominant disorder characterized by progressive ataxia, or loss of full control of bodily movements. Individuals with SCA28 may experience a range of symptoms, including difficulty with coordination and balance, speech impairments, and eye movement abnormalities. Given its genetic basis, identifying carriers or affected individuals early can be pivotal in managing the condition and understanding its progression.
DNA Labs UAE offers a specialized genetic test aimed at detecting mutations in the AFG3L2 gene to diagnose Spinocerebellar Ataxia Type 28. This test is particularly valuable for individuals with a family history of SCA28 or those exhibiting symptoms associated with the condition. By utilizing advanced genetic sequencing technologies, DNA Labs UAE provides accurate and reliable results, which are crucial for making informed decisions about treatment and management strategies.
The cost of the AFG3L2 gene test for Spinocerebellar Ataxia Type 28 at DNA Labs UAE is 4400 AED. Given the complexity of the genetic analysis and the profound impact that the results can have on patients and their families, this test represents a significant step forward in the personalized care and management of genetic disorders.
The FLRT1 gene, associated with SPG68, plays a critical role in our genetic makeup, influencing various bodily functions and developmental processes. SPG68 is a condition categorized under hereditary spastic paraplegias (HSP), which are a group of genetic disorders characterized by progressive weakness and spasticity of the legs. The FLRT1-related genetic test is a specialized diagnostic tool designed to detect mutations in the FLRT1 gene, which can help in confirming a diagnosis of SPG68.
This test is particularly important for individuals showing symptoms of HSP or those with a family history of the condition, as it can provide definitive genetic evidence of SPG68. Early diagnosis through genetic testing like the FLRT1 test can aid in the management of the condition, allowing healthcare providers to tailor treatment plans more effectively and offer genetic counseling for affected families.
The FLRT1 gene SPG68-related genetic test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the comprehensive insights it offers into the individual's genetic health concerning the FLRT1 gene and SPG68. By opting for this test at DNA Labs UAE, patients and healthcare providers can expect high-quality diagnostic services, supported by advanced genetic testing technologies and expert interpretations.
The SPG7 gene is associated with a condition known as spastic paraplegia 7 (SPG7), a form of hereditary spastic paraplegia. This genetic disorder is characterized by progressive weakness and stiffness of the legs, resulting from the degeneration of nerve pathways responsible for muscle movement and sensation. The SPG7 gene encodes a protein called paraplegin, which is involved in the maintenance and function of mitochondria, the energy-producing structures within cells. Mutations in the SPG7 gene disrupt the normal function of paraplegin, leading to the symptoms associated with the condition.
To diagnose this genetic condition, an SPG7 genetic test is conducted. This test specifically looks for mutations in the SPG7 gene that are known to cause spastic paraplegia 7. It is a crucial step in confirming the diagnosis, understanding the inheritance pattern, and guiding management and treatment decisions for affected individuals and their families.
In the UAE, DNA Labs UAE offers the SPG7 genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with advanced genetic testing technology to ensure accurate and reliable results. By opting for this test, patients and their healthcare providers can gain valuable insights into the genetic basis of their condition, enabling a more tailored approach to treatment and management.
The ZFR Gene SPG71 ZFR Related Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the ZFR gene, which have been associated with a rare neurological disorder known as Spastic Paraplegia 71 (SPG71). This condition is part of a group of disorders known as hereditary spastic paraplegias, which are characterized by progressive stiffness and weakness in the legs. The ZFR gene plays a crucial role in the normal functioning of cells, and mutations in this gene can lead to the symptoms observed in SPG71.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, this test provides critical information for the accurate diagnosis and management of individuals suspected to have SPG71. The test involves analyzing the patient's DNA to identify any abnormalities in the ZFR gene that could be responsible for the condition. This genetic testing is vital for confirming the diagnosis, understanding the prognosis, and making informed decisions about the management of the disorder.
The cost of the ZFR Gene SPG71 ZFR Related Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, including the advanced technology and expertise required to accurately detect mutations in the ZFR gene. For patients and families dealing with the challenges of hereditary spastic paraplegia, this test offers a crucial step towards achieving a clear diagnosis and exploring potential treatment options.
The REEP2 Gene SPG72 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the REEP2 gene, which is associated with the development of hereditary spastic paraplegia 72 (SPG72). SPG72 is a rare neurological disorder characterized by progressive weakness and spasticity of the legs. The test is crucial for individuals who exhibit symptoms of the disorder or have a family history of SPG72, as it helps in confirming the diagnosis, understanding the disease progression, and making informed decisions about management and therapy.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA to detect any genetic abnormalities in the REEP2 gene. The procedure is known for its accuracy and reliability, providing essential insights into the genetic basis of the condition.
The cost of the REEP2 Gene SPG72 Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of the information it provides for affected individuals and their families cannot be overstated. It not only facilitates a better understanding of the condition but also aids in the planning of treatment strategies that can improve the quality of life for those diagnosed with SPG72.
The "CPT1C Gene SPG73 Genetic Test" is a specialized diagnostic tool designed to identify mutations in the CPT1C gene, which have been associated with spastic paraplegia 73 (SPG73), a rare neurological disorder characterized by progressive weakness and stiffness of the legs. This genetic testing is crucial for individuals displaying symptoms of SPG73, as it can provide definitive diagnosis, enabling tailored management and treatment plans. Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability. The cost of the test is set at 4400 AED, reflecting the sophisticated technology and expertise involved in detecting the specific gene mutations responsible for the condition. This test is a significant step forward in the field of neurogenetics, offering hope and direction for affected individuals and their families.
The WASHC5 Gene SPG8 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to identify mutations in the WASHC5 gene, which are associated with Spastic Paraplegia 8 (SPG8). SPG8 is a rare genetic disorder characterized by progressive weakness and spasticity of the lower limbs. Early and accurate detection through this genetic test can be crucial for the management and treatment of the condition. The test involves collecting a DNA sample from the patient, which is then analyzed for specific genetic alterations in the WASHC5 gene that are indicative of SPG8. DNA Labs UAE provides this comprehensive genetic testing service for a cost of 4400 AED. This test is essential for individuals with a family history of SPG8 or those exhibiting symptoms, as it can offer critical insights into their condition and guide healthcare professionals in developing an effective treatment plan.
The MYOT Gene Spheroid Body Myopathy Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the MYOT gene, which are associated with the development of Spheroid Body Myopathy (SBM). SBM is a rare, inherited muscle disorder characterized by muscle weakness and the presence of spheroid bodies within muscle fibers, visible under a microscope. The condition is progressive and can lead to significant impairment over time.
This genetic test is crucial for individuals with a clinical presentation suggestive of SBM or those with a family history of the disease, as early and accurate diagnosis is key to managing symptoms and planning for potential treatments. The test involves analyzing the patient's DNA, extracted from a blood sample, to identify any mutations in the MYOT gene that are linked to the condition.
At DNA Labs UAE, the cost of the MYOT Gene Spheroid Body Myopathy Genetic Test is 4400 AED. This cost includes the full process of sample collection, DNA analysis, and a comprehensive report detailing the findings. The results from this test can provide invaluable information for affected individuals and their families, guiding clinical decisions and genetic counseling. It is a critical step towards personalized medicine for patients with this rare genetic disorder.
